| Revista: | Revista de investigación clínica |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000454151 |
| ISSN: | 0034-8376 |
| Autores: | Rosado Canto, Rodrigo1 Carrillo Pérez, Diego L1 Jiménez, José V1 Cuellar Rodríguez, Jennifer2 Parra Avila, Idalia1 Alberú, Josefina3 Morales Buenrostro, Luis E1 |
| Instituciones: | 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Departamento de Nefrología y Metabolismo Mineral, Ciudad de México. México 2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Departamento de Enfermedades Infecciosas, Ciudad de México. México 3Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Departamento de Trasplantes, Ciudad de México. México |
| Año: | 2019 |
| Periodo: | Jul-Ago |
| Volumen: | 71 |
| Número: | 4 |
| Paginación: | 265-274 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | Background There is no specific antiviral treatment for parvovirus B19 (PVB19) infection. Objective The objective of this study was to study the treatment and outcome of PVB19 infection in kidney transplant recipients (KTR) at our institution, and cases published in the medical literature. Methods We conducted a retrospective review of PVB19 infection in KTR at an academic medical center over a 16-year period and summarized the data on its treatment and outcome in 120 KTR in the medical literature. Results In our cohort of eight patients, the median time to the onset of PVB19 disease was 7.2 weeks after transplantation. All patients had severe aregenerative anemia (mean hemoglobin (Hb) of 6.2 ± 1.0 g/dl); all were treated with a reduction in their immunosuppressive regimen and the administration of single-dose intravenous immunoglobulin (IVIG) (mean total dosage of 0.87 ± 0.38 g/kg). The median time to anemia improvement (Hb >10 g/dl) was 3-week post-treatment. No recurrences were documented during follow-up (median 25 months). Among 128 patients (including our cohort of 8 and 120 reported in literature), therapeutic strategies included: 43% IVIG alone, 39% IVIG and reduced immunosuppression, 9% reduction of immunosuppression, and 9% conservative therapy. Clinical relapses were observed in 35% of 71 reported cases. Conclusions In KTR, decreasing immunosuppression and the administration of low-dose immunoglobulin seem to be not worse than the standard dose in PVB19 infection |
| Disciplinas: | Medicina |
| Palabras clave: | Nefrología, Terapéutica y rehabilitación, Trasplante de riñón, Infecciones virales, Parvovirus humano B19, Inmunoglobulina intravenosa |
| Keyword: | Nephrology, Therapeutics and rehabilitation, Kidney transplantation, Viral infections, Human parvovirus B19, Intravenous immunoglobulin |
| Texto completo: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
